What Physicians Want: Less of Promotional Content

Spain Reps Tick Right Boxes

Healthcare professionals are inundated by product-related promotional content from pharma firms and want less of that but more on areas such as safety, efficacy and real-world evidence, a new survey on engaging digitally-savvy physicians indicates. Spain emerges as a stand-out market where pharma appears to have fared relatively well in mapping physician preferences to their marketing activities.

Doctor webinar — Pharma Needs To Engage With HCPs More Efficiently • Source: Alamy

Healthcare Professionals (HCP)s may have turned more digitally savvy than ever amid the pandemic but pharma hasn’t quite delivered the goods so far in terms of effective or customer-centric engagement with physicians, a new global survey by Indegene, a global provider of healthcare solutions to the industry, indicates.

The study, which covered 984 physicians across the US, Europe, India and China, revealed that 70% of HCPs felt that pharma companies' sales reps do not completely understand their needs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

02 Jun 2025

• By Kevin Grogan

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

02 Jun 2025

• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

Quick Listen: Scrip’s Five Must-Know Things

02 Jun 2025

• By Ian Haydock

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

30 May 2025

• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Public Health And Innovation: Addressing Gaps, Pharma’s Role

02 Jun 2025

• By Anju Ghangurde

Expert panel including Ashok Venkitaraman, Director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.